Clinical trial
Safety Study of Alfalastin (Human Alpha-1 Antitrypsin, 33.33 mg/ml) Administered at Home to Patients Suffering From Severe Forms of Primary Deficiency in Alpha-1 Antitrypsin, Phenotype PIZZ or PISZ, With Pulmonary Emphysema.
NCT01676688 is registered in ClinicalTrials.gov with Laboratoire français de Fractionnement et de Biotechnologies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety Study of Alfalastin (Human Alpha-1 Antitrypsin, 33.33 mg/ml) Administered at Home to Patients Suffering From Severe Forms of Primary Deficiency in Alpha-1 Antitrypsin, Phenotype PIZZ or PISZ, With Pulmonary Emphysema.
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- October 31, 2012
- Enrollment
- 17 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.